UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:- Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certolizumab pegol) combined with optimized methotrexate treatment in DMARD-naive, recently diagnosed, adult rheumatoid arthritis patients with moderate-to-severe disease activity and poor prognostic factors- Long term efficacy and safety data reinforcing the clinical profile of CIMZIA® in patients with moderate-to-severe rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis- Three new studies on investigational treatments for systemic lupus erythematosus and Sjogren's Syndrome

ATLANTA, Nov. 6, 2015 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is presenting 19 studies of CIMZIA® (certolizumab pegol) and investigational medicines for systemic lupus erythematosus (SLE) and Sjogren's Syndrome at the American College of Rheumatology (ACR) 2015 Annual Scientific Meeting, being held in San Francisco, CA from November 6-11. "The CIMZIA® studies contribute to the clinical understanding of this established therapy and will help rheumatologists make the most informed treatment decisions for their patients. Notably, findings from Period 1 of the C-EARLY™ study demonstrated the...